Candida auris: A Latent Threat to Critically Ill Patients with Coronavirus Disease 2019. Clin Infect Dis.
Rodriguez JY, Le Pape P, Lopez O, Esquea K, Labiosa AL, Alvarez-Moreno C. 2/11/2021.
We read the article by White et al [1] with great interest. The proposed strategy will probably elucidate the true role of coronavirus disease 2019 (COVID-19)–associated invasive fungal infections, especially COVID-19–associated pulmonary aspergillosis (CAPA). We have not found the same incidence of CAPA, probably due to the absence of an active search. However, we detected an increase in the number of fungemias in critically ill COVID-19 patients.
Real-World Use of Generic Meropenem: Results of an Observational Study. Antibiotics (Basel).
Garnica-Velandia S, Aristizábal-Ruiz LA, Alvarez-Moreno CA. 11/1/2021
Abstract
Background: To determine the therapeutic effect and tolerability of meropenem in routine clinical practice, in terms of clinical and microbiological response. Methods: A real-world, observational, descriptive, longitudinal study with daily monitoring of clinical history records was conducted on all patients who were medically prescribed meropenem during a period between October 2015 and March 2016 at a university hospital in Bucaramanga (Colombia).
